Omnes Capital's investments

AgomAb was founded through a collaboration between argenx and the University of Torino, Italy, based on the groundbreaking work of Paolo Michieli and his translational medicine team. The Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues and has produced a comprehensive preclinical package illustrating different applications in the fields of fibrotic, inflammatory, autoimmune and degenerative diseases. Based in Ghent Belgium, it is backed by an International syndicate of experienced life sciences venture capital investors.

Teach on Mars is a 100% mobile-native learning technology provider. Our solution helps today’s organisations connect people with the learning and the communities they need to do their jobs and live their lives better. Winner of numerous industry awards, Teach on Mars is recognised as European leader in the mobile learning space. Since its foundation in 2013, the company has delivered its solution to over 100 blue-chip clients, in 20+ languages across more than 60 countries throughout the globe, and today it has bases in Sophia-Antipolis, Paris, Milan and London. 60 Teach on Mars staff and an extensive worldwide network of 40+ content and technology partners collaborate to equip organisations with the toolset, mindset and skillset required to create their next-generation learning ecosystem. And because Teach on Mars takes its responsibility for the future of our planet seriously, it invests 1% of its revenues in education projects contributing directly to the UNESCO Sustainsable Development Goals.